UniQure NV (QURE) - Financial and Strategic SWOT Analysis Review
- GDPH389133FSA
- Pages: 53
- October 2018
- Total Views:1144
- Region : Europe
- GlobalData
- Equity Research Report

Details
UniQure NV (QURE)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description-A detailed description of the company's operations and business divisions.
- Corporate strategy-Analyst's summarization of the company's business strategy.
- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history-Progression of key events associated with the company.
- Major products and services-A list of major products, services and brands of the company.
- Key competitors-A list of key competitors to the company.
- Key employees-A list of the key executives of the company.
- Executive biographies-A brief summary of the executives' employment history.
- Key operational heads-A list of personnel heading key departments/functions.
- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities-A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
UniQure NV (UniQure) develops and markets gene therapy products. The company develops adeno-associated virus based gene therapies using its gene technology platform. UniQure offers clinical and preclinical programs for lipoprotein lipase deficiency, hemophilia A and B, Huntington's disease, congestive heart failure and other research targets. The company develops a gene platform to bring new disease modifying therapies to patients with genetic diseases. The company conducts drug discovery and preclinical research in collaboration with academic research institutions. UniQure is headquartered in Amsterdam, the Netherlands.
UniQure NV Key Recent Developments
Sep 28,2018: uniQure to Participate in Multiple Upcoming Industry Conferences
Aug 23,2018: uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
Aug 08,2018: uniQure announces second quarter 2018 financial results and highlights company progress
Jun 13,2018: uniQure Announces New Appointments to its Board of Directors
May 18,2018: uniQure presents preclinical data demonstrating advances in the distribution of gene therapy
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1-About the Company 6
UniQure NV-Key Facts 6
UniQure NV-Key Employees 7
UniQure NV-Key Employee Biographies 8
UniQure NV-Major Products and Services 10
UniQure NV-History 11
UniQure NV-Company Statement 13
UniQure NV-Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2-Company Analysis 16
Company Overview 16
UniQure NV-Business Description 17
R&D Overview 17
UniQure NV-Corporate Strategy 18
UniQure NV-SWOT Analysis 19
SWOT Analysis-Overview 19
UniQure NV-Strengths 19
UniQure NV-Weaknesses 20
UniQure NV-Opportunities 21
UniQure NV-Threats 22
UniQure NV-Key Competitors 23
Section 3-Company Financial Ratios 24
Financial Ratios-Capital Market Ratios 24
Financial Ratios-Annual Ratios 25
Performance Chart 27
Financial Performance 27
Financial Ratios-Interim Ratios 28
Financial Ratios-Ratio Charts 29
Section 4-Company's Lifesciences Financial Deals and Alliances 30
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
UniQure NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31
UniQure NV, Recent Deals Summary 32
Section 5-Company's Recent Developments 33
Aug 23, 2018: uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B 33
Aug 23, 2018: uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B 35
Aug 08, 2018: uniQure announces second quarter 2018 financial results and highlights company progress 37
Jun 13, 2018: uniQure Announces New Appointments to its Board of Directors 40
May 18, 2018: uniQure presents preclinical data demonstrating advances in the distribution of gene therapy 41
Apr 27, 2018: uniQure Announces to Present at Multiple Conferences in May 42
Mar 14, 2018: uniQure Announces 2017 Financial Results and Recent Company Progress 43
Feb 27, 2018: uniQure to Participate in Multiple Conferences in March 45
Jan 08, 2018: uniQure Provides Year-End 2017 Corporate Update and Outlines Near-Term Objectives to Further Drive Shareholder Value 46
Dec 11, 2017: uniQure Added to NASDAQ Biotechnology Index 48
Section 6-Appendix 49
Methodology 49
Ratio Definitions 49
About GlobalData 53
Contact Us 53
Disclaimer 53
List Of Figure
List of Figures
UniQure NV, Performance Chart (2013-2017) 27
UniQure NV, Ratio Charts 29
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
UniQure NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 31
List Of Table
List of Tables
UniQure NV, Key Facts 6
UniQure NV, Key Employees 7
UniQure NV, Key Employee Biographies 8
UniQure NV, Major Products and Services 10
UniQure NV, History 11
UniQure NV, Subsidiaries 15
UniQure NV, Key Competitors 23
UniQure NV, Ratios based on current share price 24
UniQure NV, Annual Ratios 25
UniQure NV, Annual Ratios (Cont...1) 26
UniQure NV, Interim Ratios 28
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
UniQure NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31
UniQure NV, Recent Deals Summary 32
Currency Codes 49
Capital Market Ratios 49
Equity Ratios 50
Profitability Ratios 50
Cost Ratios 51
Liquidity Ratios 51
Leverage Ratios 52
Efficiency Ratios 52
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
UniQure NV, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts
Companies
Freeline Therapeutics Ltd
Expression Therapeutics LLC
bluebird bio Inc
BioMarin Pharmaceutical Inc
Bayer Corporation
AveXis Inc
Audentes Therapeutics Inc
Applied Genetic Technologies Corp
Adverum Biotechnologies Inc
Company Profile
Company Profile Title
UniQure NV (QURE)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description-A detailed description of the company's operations and business divisions.
- Corporate strategy-Analyst's summarization of the company's business strategy.
- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history-Progression of key events associated with the company.
- Major products and services-A list of major products, services and brands of the company.
- Key competitors-A list of key competitors to the company.
- Key employees-A list of the key executives of the company.
- Executive biographies-A brief summary of the executives' employment history.
- Key operational heads-A list of personnel heading key departments/functions.
- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities-A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
UniQure NV (UniQure) develops and markets gene therapy products. The company develops adeno-associated virus based gene therapies using its gene technology platform. UniQure offers clinical and preclinical programs for lipoprotein lipase deficiency, hemophilia A and B, Huntington's disease, congestive heart failure and other research targets. The company develops a gene platform to bring new disease modifying therapies to patients with genetic diseases. The company conducts drug discovery and preclinical research in collaboration with academic research institutions. UniQure is headquartered in Amsterdam, the Netherlands.
UniQure NV Key Recent Developments
Sep 28,2018: uniQure to Participate in Multiple Upcoming Industry Conferences
Aug 23,2018: uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
Aug 08,2018: uniQure announces second quarter 2018 financial results and highlights company progress
Jun 13,2018: uniQure Announces New Appointments to its Board of Directors
May 18,2018: uniQure presents preclinical data demonstrating advances in the distribution of gene therapy
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1-About the Company 6
UniQure NV-Key Facts 6
UniQure NV-Key Employees 7
UniQure NV-Key Employee Biographies 8
UniQure NV-Major Products and Services 10
UniQure NV-History 11
UniQure NV-Company Statement 13
UniQure NV-Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2-Company Analysis 16
Company Overview 16
UniQure NV-Business Description 17
R&D Overview 17
UniQure NV-Corporate Strategy 18
UniQure NV-SWOT Analysis 19
SWOT Analysis-Overview 19
UniQure NV-Strengths 19
UniQure NV-Weaknesses 20
UniQure NV-Opportunities 21
UniQure NV-Threats 22
UniQure NV-Key Competitors 23
Section 3-Company Financial Ratios 24
Financial Ratios-Capital Market Ratios 24
Financial Ratios-Annual Ratios 25
Performance Chart 27
Financial Performance 27
Financial Ratios-Interim Ratios 28
Financial Ratios-Ratio Charts 29
Section 4-Company's Lifesciences Financial Deals and Alliances 30
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
UniQure NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31
UniQure NV, Recent Deals Summary 32
Section 5-Company's Recent Developments 33
Aug 23, 2018: uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B 33
Aug 23, 2018: uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B 35
Aug 08, 2018: uniQure announces second quarter 2018 financial results and highlights company progress 37
Jun 13, 2018: uniQure Announces New Appointments to its Board of Directors 40
May 18, 2018: uniQure presents preclinical data demonstrating advances in the distribution of gene therapy 41
Apr 27, 2018: uniQure Announces to Present at Multiple Conferences in May 42
Mar 14, 2018: uniQure Announces 2017 Financial Results and Recent Company Progress 43
Feb 27, 2018: uniQure to Participate in Multiple Conferences in March 45
Jan 08, 2018: uniQure Provides Year-End 2017 Corporate Update and Outlines Near-Term Objectives to Further Drive Shareholder Value 46
Dec 11, 2017: uniQure Added to NASDAQ Biotechnology Index 48
Section 6-Appendix 49
Methodology 49
Ratio Definitions 49
About GlobalData 53
Contact Us 53
Disclaimer 53
List Of Figure
List of Figures
UniQure NV, Performance Chart (2013-2017) 27
UniQure NV, Ratio Charts 29
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
UniQure NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 31
List Of Table
List of Tables
UniQure NV, Key Facts 6
UniQure NV, Key Employees 7
UniQure NV, Key Employee Biographies 8
UniQure NV, Major Products and Services 10
UniQure NV, History 11
UniQure NV, Subsidiaries 15
UniQure NV, Key Competitors 23
UniQure NV, Ratios based on current share price 24
UniQure NV, Annual Ratios 25
UniQure NV, Annual Ratios (Cont...1) 26
UniQure NV, Interim Ratios 28
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
UniQure NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31
UniQure NV, Recent Deals Summary 32
Currency Codes 49
Capital Market Ratios 49
Equity Ratios 50
Profitability Ratios 50
Cost Ratios 51
Liquidity Ratios 51
Leverage Ratios 52
Efficiency Ratios 52
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
UniQure NV, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts
Companies
Freeline Therapeutics Ltd
Expression Therapeutics LLC
bluebird bio Inc
BioMarin Pharmaceutical Inc
Bayer Corporation
AveXis Inc
Audentes Therapeutics Inc
Applied Genetic Technologies Corp
Adverum Biotechnologies Inc